PURPOSE: To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. RESULTS: One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. CONCLUSION: Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancer patients who may derive benefit from erlotinib treatment.
PURPOSE: To evaluate the efficacy and safety of erlotinib in advanced breast cancer. Experimental design Multicenter, phase II study of erlotinib (150 mg orally daily). Cohort 1: progression after anthracyclines, taxanes, and capecitabine (n = 47). Cohort 2: progression after >1 chemotherapy for advanced-stage disease (n = 22). Primary endpoint was response rate (World Health Organization criteria). Secondary endpoints were safety, time to progression, and survival. RESULTS: One patient in each cohort (n = 2, 3.0%) had a partial response. Response duration was 17 weeks for the Cohort 1 patient and 32 weeks for the Cohort 2 patient. Median time to progression was 43 days for Cohort 1 (range 1-204) and 43 days for Cohort 2 (range 25-419). Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia. CONCLUSION:Erlotinib had minimal activity in unselected previously treated women with advanced breast cancer. Predictive factors are needed to identify breast cancerpatients who may derive benefit from erlotinib treatment.
Authors: Fan Zhang; Jie Zhang; Moyan Liu; Lichao Zhao; RuiXia LingHu; Fan Feng; Xudong Gao; Shunchang Jiao; Lei Zhao; Yi Hu; Junlan Yang Journal: Oncoimmunology Date: 2015-01-22 Impact factor: 8.110
Authors: Clinton F Stewart; Michael Tagen; Lee S Schwartzberg; L Johnetta Blakely; Kurt W Tauer; Linda M Smiley Journal: Cancer Chemother Pharmacol Date: 2014-01-22 Impact factor: 3.333
Authors: Hiroko Masuda; Dongwei Zhang; Chandra Bartholomeusz; Hiroyoshi Doihara; Gabriel N Hortobagyi; Naoto T Ueno Journal: Breast Cancer Res Treat Date: 2012-10-17 Impact factor: 4.872
Authors: Maura N Dickler; Hope S Rugo; Carey A Eberle; Edi Brogi; James F Caravelli; Katherine S Panageas; Jeff Boyd; Benjamin Yeh; Diana E Lake; Chau T Dang; Teresa A Gilewski; Jacqueline F Bromberg; Andrew D Seidman; Gabriella M D'Andrea; Mark M Moasser; Michele Melisko; John W Park; Janet Dancey; Larry Norton; Clifford A Hudis Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531